Magazine

Most Recent

Government Briefs

June 27, 1988

Hitting The Magic Billion-Dollar Mark The recent AIDS report by the Institute of Medicine got a lot of play in the press for its criticism of federal efforts on behalf of drug abusers and AIDS sufferers facing discrimination. But the report also contains an important message for researchers. Entitled Confronting AIDS: Update 1988” because it follows up on IOM’s landmark 1986 report, the study calls on the NIH director to evaluate how well the government is spending its money in a s

0 Comments

Hot Papers

June 27, 1988

The articles listed below, all less than a year old, have received a substantially greater number of citations than those in the same subject area and of the same vintage. A citation-tracking algorithm of the Institute for Scientific Information has identified these articles. G. Baskaran, Z. Zou, E.W. Anderson, “The resonating valence bond state and high-Tc superconductivity. a mean field theory,” Solid State Communcations, 63 (11), 973-6, September 1987 P.J. Bjorkman, M.A. Saper, B.

0 Comments

A new generation of dot-matrix printers has hit the market, and these devices are ideal for the scientist whose institution can’t af- ford to put a laser printer in every office. The new 24-pin units provide better print quality and more time-saving features than older 24-pin printers, yet they cost much less than laser printers. Now a small laboratory can get high-resolution text and graphics (180 X 360 dote per square inch) for what used to be a low-resolution-only price of aroun

0 Comments

Industry Briefs

June 27, 1988

Pairing Youth And Experience By combining the long experience of SmithKline Beckman with the scientific expertise of Nova Pharmaceutical, the two drug companies hope to develop new therapies with which to treat central nervous system diseases. Under a partnership announced last month and awaiting stockholder approval, SmithKline Beckman would specifically target $49 million over the next seven years for central nervous system research performed by the Baltimore company (The Scientist, May 16,

0 Comments

This year’s job market is the hottest yet for new Ph.D.’s in agricultural sciences specializing in engineering, economics, and biotechnology-related fields, according to the department chairmen polled by The Scientist. “The market has been very good for several years, and I don’t think we’ve seen the peak at all yet,” says Gerald Isaacs, chairman of agricultural engineering at the University of Florida. The same story comes from the West Coast. “As

0 Comments

The tragic loss of the space shuttle Challenger has not only disrupted the U.S. space program, it has also disrupted the process for planning the program. The current debate over the manned space station and the commercially developed space facility, an unmanned platform that would be launched and serviced by the shuttle in the early 1990s, is symptomatic of the present disarray. NASA’s problem is that it continues to employ a supply-side policy of investing in space. This is true for b

0 Comments

Letters

By | June 27, 1988

Illogical Pathways Eugene Garfield in his editorial on “Recognizing the Role of Chance” (May 2, page 10) touches upon a point of more realistically reporting the role of serendipity in the research process. This is only one aspect of the publication of scientific papers that needs more discussion and consensus among scientists. I have long felt that the gloss of a hypothetico-deductive style in a research paper may overstate the degree of support for an author’s claim, if

0 Comments

Little Science, Big Science--And Global Science

By | June 27, 1988

The handwriting for the future of federal science funding is on the wall, and Frank Press has read it as well as anybody. In his April 26th speech, the National Academy of Sciences president uttered publicly what many have acknowledged privately. The United States cannot afford to pursue at full tilt its Big Science agenda—the superconducting supercoilider, the human genome project, the space station—without cutting into support for the legions of individual investigators represe

0 Comments

Major Drug Firms Also See Potential

By | June 27, 1988

The promise of profit in neurobiology is exciting the neurons of venture capitalists all over the country (see accompanying story). It’s also stimulating gray matter at the stoic nerve centers of the pharmaceutical giants. Although they may be loathe to admit it, beneath the traditionally calm exterior at these companies, synapses—and scientists—are jumping. Some of the large companies, of course, have been searching for drugs that affect the central nervous system for years

0 Comments

First ‘superchemist’ Ed Engler threw corporate hierarchy to the winds, then IBM promoted him for it None of his IBM colleagues would have ever guessed that Edward Engler was about to turn his career upside-down on that February day in 1987. But looking back on it, the signs were there. Everyone knew this about Engler: The 39-year-old chemist was moving smartly along Big Blue’s management track. Already a second-tier manager, he had four laboratory directors reporting to hi

0 Comments

Popular Now

  1. So You’ve Been Mistaken as a White Nationalist
  2. Opinion: We Need a Replacement for Beall’s List
  3. Your Body Is Teeming with Weed Receptors
    Features Your Body Is Teeming with Weed Receptors

    And the same endocannabinoid system that translates marijuana's buzz-inducing compounds into a high plays crucial roles in health and disease outside the brain.

  4. Doctors’ Advice to Finish Antibiotics Overlooks Resistance
AAAS